Suppliers and packagers for cetraxal

cetraxal

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Lab Salvat	CETRAXAL	ciprofloxacin hydrochloride	SOLUTION/DROPS;OTIC	021918	NDA	Xspire Pharma, Llc	42195-550-14	14 CONTAINER in 1 CARTON (42195-550-14) / .25 mL in 1 CONTAINER	2012-08-27
Lab Salvat	CETRAXAL	ciprofloxacin hydrochloride	SOLUTION/DROPS;OTIC	021918	NDA	Wraser Llc	66992-450-14	14 CONTAINER in 1 CARTON (66992-450-14) / .25 mL in 1 CONTAINER	2009-05-14

Suppliers for the Pharmaceutical Drug: Cetraxal

Last updated: August 6, 2025

Introduction

Cetraxal, the branded formulation of ciprofloxacin ear drops, is a widely prescribed topical antibiotic for outer ear infections (otitis externa) and other related conditions. Its active ingredient, ciprofloxacin, belongs to the fluoroquinolone class of antibiotics, known for broad-spectrum antibacterial activity. As a critical medicinal product, the supply chain for Cetraxal involves various stakeholders, including the original patent holders, generic pharmaceutical companies, contract manufacturing organizations, and distributors. This article examines the key suppliers, manufacturing landscape, and market dynamics underpinning Cetraxal's availability globally.

Original Manufacturer and Patent Holders

The original version of Cetraxal was developed and marketed by Alcon Laboratories, a diversified ophthalmic and dermatological pharmaceutical firm now integrated into Novartis Pharmaceuticals. Launched in the early 2000s, Alcon held exclusive rights to commercialize Cetraxal and control its production and distribution through licensing agreements and patent protections.

Alcon’s early patent protections provided a temporary monopoly, allowing the firm to maintain high margins. However, as patents expired in various jurisdictions—most notably in the United States in the early 2010s—the market opened to generic manufacturers. These developments significantly increased the number of suppliers and the overall supply chain complexity for Cetraxal.

Generic Ciprofloxacin Ear Drops Suppliers

With patent timelines elapsing, numerous generic pharmaceutical companies gained approval to produce ciprofloxacin ear drops, often marketed under different brand names or as unbranded generics. Several key players have emerged as primary suppliers of high-quality, bioequivalent Ciprofloxacin formulations:

• Sandoz (Novartis International AG)

  • As a division of Novartis, Sandoz manufactures generic ciprofloxacin ear drops, leveraging established manufacturing excellence and global distribution networks.

• Mylan (now part of Viatris)

  • Mylan has supplied ciprofloxacin topicals in multiple countries, often offering cost-effective alternatives to branded options.

• Teva Pharmaceutical Industries Ltd.

  • A leading generics manufacturer, Teva produces ciprofloxacin ear drops that meet international quality standards for safety and efficacy.

• Aurobindo Pharma Ltd.

  • Based in India, Aurobindo is a significant supplier of generic ciprofloxacin formulations, including otic solutions, with approvals in various markets.

• Sun Pharmaceutical Industries Ltd.

  • Also headquartered in India, Sun Pharma produces ciprofloxacin ear drop formulations, widely available in Asia and emerging markets.

These manufacturers typically employ contract manufacturing organizations (CMOs) to scale production and ensure quality control throughout the supply chain.

Manufacturing and Supply Chain Dynamics

Manufacturing processes:

Producing ciprofloxacin ear drops involves complex formulation procedures to ensure stability, sterility, and bioavailability. Contract manufacturing organizations with Good Manufacturing Practice (GMP) certification usually undertake large-scale production, adhering strictly to regulatory standards set by agencies such as the FDA, EMA, and WHO.

Supply chain considerations:

• Raw materials sourcing: Ciprofloxacin is synthesized through multi-step chemical processes, relying on raw materials globally sourced for cost efficiency.
• Quality control: Stringent testing ensures purity, absence of contaminants, and stability under various storage conditions.
• Distribution channels: Post-manufacture, the distribution involves wholesalers, regional distributors, and direct supply to hospitals and pharmacies. The complexity increases in developing regions due to logistical challenges.

Market Dynamics and Regulatory Landscape

The entry of multiple generic manufacturers has significantly lowered the cost of ciprofloxacin ear drops, expanding access worldwide. Regulatory agencies have harmonized approval processes, but approval may vary based on formulations and local requirements.

Patent expirations and patent challenges have fostered increased supplier diversity, leading to a competitive landscape. However, the quality assurance standards remain essential for suppliers, given the critical nature of ophthalmic and otic antibiotics.

Emerging Suppliers and Market Trends

• Local manufacturing in emerging markets: Countries like India, China, and Brazil have developed robust ophthalmic and otic pharmaceutical sectors.
• Increased focus on biosimilar and generic quality: Regulators now impose stricter bioequivalence and stability testing, limiting subpar suppliers' market access.
• Supply chain resilience: The COVID-19 pandemic underscored the necessity for diversified supplier bases and strategic stockpiling strategies to prevent shortages.

Conclusion

The supply landscape for Cetraxal hinges upon a layered network starting with original patent holders like Novartis’s Alcon, followed by numerous generic manufacturers including Sandoz, Mylan, Teva, Aurobindo, and Sun Pharma. The expiration of patents catalyzed market democratization, enabling a broader array of trusted suppliers. Ensuring consistent quality, reliable manufacturing, and compliance with global regulatory standards remains a priority for all stakeholders.

---

Key Takeaways

• Diversification of Suppliers: Post-patent expiration, multiple manufacturers have entered the Ciprofloxacin ear drops market, ensuring supply stability but necessitating rigorous quality assurance.
• Regulatory Stringency: Suppliers must comply with GMP standards across jurisdictions; regulatory approval remains a critical indicator of reliability.
• Global Manufacturing hubs: India and China serve as pivotal centers for generic Ciprofloxacin production, supporting global demand.
• Supply Chain Resilience: Geographic diversification and strategic inventories are vital to mitigate risks like shortages or disruptions.
• Market Competition: Cost competitiveness has increased, improving accessibility, especially in low- and middle-income countries.

---

FAQs

1. Who are the main current suppliers of Cetraxal?
Major generic suppliers include Sandoz (Novartis), Aurobindo Pharma, Sun Pharma, Teva, and Mylan (Viatris). These companies produce bioequivalent ciprofloxacin ear drops distributed globally.

2. How does patent expiry influence the supply of Cetraxal?
Patent expiry allows multiple generic manufacturers to produce ciprofloxacin ear drops, increasing market competition, reducing prices, and improving access in various regions.

3. Are there quality differences between branded and generic Ciprofloxacin ear drops?
Regulators require generics to meet strict bioequivalence and quality standards. Reputable manufacturers maintain high quality controls; however, unregulated or substandard products can pose risks.

4. What role do contract manufacturing organizations (CMOs) play?
CMOs enable large-scale, GMP-compliant production, ensuring supply capacity and quality consistency across different markets.

5. How does global regulation impact supply chains?
Varying approval processes, quality standards, and import regulations influence how suppliers distribute Ciprofloxacin ear drops across regions, stressing the importance of compliance for market access.

---

References

1. [1] Novartis official website and filings, 2022.
2. [2] FDA drug approval database, 2022.
3. [3] World Health Organization (WHO) guidelines on sterile pharmaceutical manufacturing, 2021.
4. [4] Indian Pharmaceutical Association, Market Analysis, 2022.
5. [5] European Medicines Agency (EMA), Bioequivalence standards, 2022.